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Cardiac embolism continues to be a leading etiology of ischemic strokes worldwide. Although 
pathologies that result in cardioembolism have not changed over the past decade, there have 
been significant advances in the treatment and stroke prevention methods for these conditions. 
Atrial fibrillation remains the prototypical cause of cardioembolic strokes. The availability of new 
long-term monitoring devices for atrial fibrillation detection such as insertable cardiac monitors 
has allowed accurate detection of this leading cause of cardioembolism. The non-vitamin K an-
tagonist oral anticoagulants have improved our ability to prevent strokes for many patients with 
non-valvular atrial fibrillation (NVAF). Advances in left atrial appendage closure and the U.S. 
Food and Drug Administration approval of the WATCHMAN (Boston Scientific) device for stroke 
prevention in NVAF patients who have an appropriate rationale for a nonpharmacological alter-
native, have revolutionized the field and provided a viable option for patients at higher hemor-
rhagic risk. The role of patent foramen ovale closure for secondary prevention in selected pa-
tients experiencing cryptogenic ischemic strokes at a relatively young age has become clearer 
thanks to the very recent publication of long-term outcomes from three major studies. Advances 
in the management of infective endocarditis, heart failure, valvular diseases, and coronary artery 
disease have significantly changed the management of such patients, but have also revealed 
new concerns related to assessment of ischemic versus hemorrhagic risk in the setting of anti-
thrombotic use. The current review article aims to discuss these advances especially as they per-
tain to the stroke neurology practice. 
Keywords Ischemic stroke; Cardioembolism; Atrial fibrillation; Anticoagulants; Left atrial appendage 
closure; Patent foramen ovale closure
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Introduction
Cardiac embolism (CE) is a leading etiology of ischemic strokes, 
the cause of 25% to 40% of cerebral infarctions worldwide. 
Cardioembolic strokes are associated with poor outcomes and 
relatively high recurrence rates compared to other ischemic 
stroke causes. The major causes of CE have not changed over 
the past decade, but significant advances in their primary 
treatment and stroke prevention methods have been achieved. 
Atrial fibrillation (AF) remains the prototypical cause of CE. Ex-
ternal prolonged monitoring methods have allowed better de-
tection of paroxysmal AF, and more recently, insertable cardiac 
monitors (ICMs) have improved accurate detection of even brief 
AF episodes for up to 3 years.1 Although not so novel, the non-
vitamin K antagonist oral anticoagulants (NOAC) have im-
proved stroke prevention in patients with non-valvular atrial fi-
brillation (NVAF).1,2 The role of the left atrial appendage (LAA) 
in NVAF-related CE has become clearer and there have been 
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major advances in left atrial appendage closure (LAAC) result-
ing in the recent U.S. Food and Drug Administration (FDA) ap-
proval of the WATCHMAN (Boston Scientific, Marlborough, MA, 
USA) device for stroke prevention in patients with appropriate 
rationale for nonpharmacological alternatives.3 Recent publica-
tion of long-term follow up of patent foramen ovale (PFO) clo-
sure trials have changed the landscape in that field resulting in 
FDA approval of this approach for secondary stroke preven-
tion.4-6 Advances in the procedural management of infective 
endocarditis (IE), heart failure (HF), valvular disease, and coro-
nary artery disease have resulted in improvements but have 
also revealed new concerns related to assessment of ischemic 
versus hemorrhagic risk in the setting of antithrombotic use.
One revolutionary advance has been a better understanding 
of the causes and risk of another and much more severe type of 
stroke—intracerebral hemorrhage (ICH). ICHs constitute one-
third of all strokes worldwide and carry a high risk of death and 
severe disability.3,7 Oral anticoagulants (OAC) including warfarin 
and NOACs are common causes of severe ICHs. Neuroimaging 
markers that can predict first-time or recurrent ICH risk have 
been validated.3 Neurologists who are familiar with both isch-
emic and hemorrhagic stroke management need to balance the 
risks and benefits of different medical and nonpharmacological 
CE prevention approaches in conjunction with the cardiologists 
and other medical specialists. The most relevant markers of ICH 
risk are discussed in a separate paper on prevention of lacunar 
and hemorrhagic strokes published in this same issue of the 
Journal of Stroke.8 The current article will review advances in 
CE stroke prevention emphasizing the aspects most relevant to 
the practicing neurologists and stroke specialists.
Updates on stroke prevention in atrial 
fibrillation
AF, whether related to rheumatic valve disease or not, remains 
the most important cause of CE worldwide.9 The prevalence of 
AF increases with age and it is closely linked to vascular risk 
factors such as hypertension, diabetes mellitus, coronary artery 
disease, HF, thyroid dysfunction, sleep apnea, obesity, smoking, 
and alcohol consumption.1,10 About 2% of the population 
younger than 65 years, and 9% of people aged 65 years or old-
er have AF in the United States.11 The presence of AF increases 
the risk of stroke by about 5-fold in all age groups.12 Warfarin 
remains the only approved medication for valvular AF; used 
with dose-adjustment based on target international normal-
ized ratio (INR). Concurrent aspirin and warfarin use with INR 
targets of 2.5 to 3.5 is recommended for patients with me-
chanical heart valves, while warfarin alone with INR target of 
2 to 3 is used for most other patients with AF. Embolic risk 
scores such as CHADS2, CHA2DS2-VASc, and ATRIA provide esti-
mates of the risk of ischemic strokes in NVAF with some limi-
tations.1,13-15 Despite the tendency to overestimate embolic risk, 
CHA2DS2-VASc has become the most commonly used embolic 
risk score recommended by both European and American AF 
management guidelines.9,10,15,16
The cutoff score for using OACs in NVAF is ≥1 per European 
guidelines and ≥2 per the US guidelines; patients with a score 
of 1 can be managed with either OAC or antiplatelet per the 
latter. The United States guidelines also recommend a shared 
decision-making approach where the responsible clinician dis-
cusses the advantages (prevention of embolism and associated 
strokes) as well as potential risks (major hemorrhage) of OAC 
medications with the patient. The same guidelines also suggest 
periodic review and discussion of the changing risk/benefit 
profile of the preventive treatment over time. Examples to such 
changes might include: starting a patient with initially low 
CHA2DS2-VASc on anticoagulation when the risk increases with 
age or as a result of the appearance of a new risk factor; con-
sidering a patient on OAC for LAAC after sustaining ICH or 
manifesting any marker of high ICH risk such as brain micro-
bleeds. A multidisciplinary approach that includes the cardiolo-
gist, neurologist and other specialists when needed, is helpful 
for optimal management of AF patients with complications 
such as hemorrhagic risk. 
AF is also classified based on its temporal pattern as perma-
nent, persistent, or paroxysmal. The paroxysmal category can 
be missed among inpatients even after an AF-related embolic 
stroke, and longer duration outpatient monitoring (≥72 hours) 
is therefore recommended. It is important to correctly diagnose 
or rule out AF as both failure to take appropriate prevention 
measures and the unnecessary use of OAC have serious conse-
quences—embolic stroke and ICH respectively. A recent major 
advance in the field was the development of ICMs that were 
shown to be superior to conventional strategies for detecting 
AF.17 ICMs can be implanted with a very low complication risk 
(<1%) even as an outpatient and provide highly sensitive AF 
monitoring for 2 to 3 years (Figure 1).18 Other available outpa-
tient monitoring strategies include Holter (24 to 72 hours), 
mobile cardiac outpatient telemetry devices (up to 4 weeks) 
and electrocardiographic patch devices (up to 4 weeks).1 These 
external devices have a relative advantage of ease of use and 
lower cost, but require patient compliance, have reduced sen-
sitivity, and cannot be used for rhythm monitoring for longer 
than 2 to 4 weeks. The median time to detection of AF using 
ICM in a large randomized controlled trial (RCT) and the largest 
available observational cohort was 84 days (interquartile range 
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[IQR], 18 to 265) and 112 days (IQR, 35 to 293), respective-
ly.17,19 Long-term (2 to 3 years) monitoring with ICM is thus an 
attractive approach with high accuracy for AF detection, with 
minimal patient compliance. All ischemic stroke patients 
should receive at least one electrocardiogram (EKG) and should 
ideally be kept on telemetry during hospital stay. For patients 
with non-lacunar infarcts, long-term monitoring should be 
considered if no other clear stroke etiology is found. Starting 
all such patients on a NOAC without confirming the presence 
of AF does not prevent ischemic strokes better than aspirin 
alone and poses increased risk of brain hemorrhages by 4 to 
6.5 folds.20 There is a growing body of literature on the mini-
mum duration of AF before occurrence of embolic events but 
until we obtain data from properly designed RCTs, even a short 
duration (1 to 2 minutes) of unprovoked AF should trigger con-
sideration of preventive measures especially in high risk pa-
tients such as ischemic stroke survivors.
Life-long OAC use is currently the norm for stroke prevention 
in patients with AF who are not at high risk of hemorrhage. 
Warfarin decreases stroke risk by 64% compared to placebo, 
and 47% compared to aspirin in NVAF.21 Warfarin also increas-
es the risk of ICH by 5 folds compared to placebo and 2 folds 
compared to aspirin.22 In NVAF patients without past history or 
high risk for ICH, warfarin is superior to placebo and aspirin for 
preventing all strokes but not vascular death or all cause 
deaths. Warfarin therefore has been the gold standard for 
stroke prevention in NVAF patients who do not have contrain-
dications for long-term anticoagulation. 
A direct thrombin inhibitor (dabigatran) and three factor Xa 
inhibitors (rivaroxaban, apixaban, edoxaban) collectively called 
NOACs have been approved for the same indication (Table 1).23-
27 These drugs are noninferior to warfarin for overall stroke 
prevention in AF, and pose lower ICH risk.23 Dabigatran and ri-
varoxaban however, have shown higher gastrointestinal hem-
orrhage risk. These NOACs have shown a trend for mortality 
benefit compared to warfarin. They have multiple other advan-
tages including ease of use. Their effect starts within 1 to 2 
hours after the first dose and they have less food/drug interac-
tions than warfarin. They do not require blood draws as their 
effect is fairly predictable in patients without renal failure. 
Their effect wears off after 24 to 48 hours of the last dose, 
which could be an advantage in case of bleeding or if surgery 
is needed, but also potentially a disadvantage for risk of embo-
lism in patients with poor compliance (even when 1 to 2 doses 
are missed). Another advantage is that they have been proven 
to have similar efficacy to warfarin in the presence of comor-
bidities not uncommonly seen with AF such as mild HF and 
history of cardioversion. 
Idarucizumab is a humanized monoclonal antibody fragment 
that binds dabigatran, and is currently FDA-approved as a re-
versal agent for this direct thrombin inhibitor.28 Andexanet alfa, 
a modified recombinant derivative of factor Xa, was recently 
approved by FDA as a candidate reversal agent for rivaroxaban 
and apixaban.29 The clinical studies of both Idarucizumab and 
andexanet alfa provided evidence for reversal of the laboratory 
findings associated with the respective NOACs. However, none 
of these studies were randomized and we do not have evidence 
for the clinical efficacy of these reversal agents. It is important 
to use available reversal agents for NOAC-related hemorrhages, 
but it is unlikely that these drugs will improve outcomes espe-
cially in ICHs that are already sizeable or at a critical brain lo-
cation upon presentation. 
Disadvantages of NOACs include higher risk of gastrointesti-
nal side effects especially hemorrhage, safety concerns in older 
adults with renal failure, higher cost, and poor compliance as a 
result of these problems. The FDA has issued warnings against 
NOAC use in patients with mechanical valves as well as in-
creased risk of thromboembolic events even in case of 1 to 2 
missed doses. Recent real-world data also showed that more 
Figure 1. Placement of an insertable cardiac monitor. The insertable cardi-
ac monitor is placed under the skin using an injection system through a 
simple incision. Reproduced with permission of Medtronic, Inc. (http://
www.medtronic.com). 
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than half of patients receiving lower doses of NOACs, mostly 
for fear of side effects, did not have any indication for the low-
er dose.30 It is important to use the appropriate doses of these 
medications as the use of lower and higher doses are associat-
ed with elevated ischemic and hemorrhagic risks, respectively.
All OACs, including NOACs, significantly increase the risk of 
ICH and other major and minor bleeding risks.31 None of the 
phase 3 NOAC studies included patients with past history of 
ICH or known high bleeding risk, so the effects of NOACs on 
such patients are unknown. Even in survivors of embolic ap-
pearing cerebral infarct at low baseline ICH risk, NOAC use was 
associated with a 4- to 6.5-fold higher risk of brain hemor-
rhages compared to aspirin in a recently published RCT (NAVI-
GATE ESUS).20 It is also well-known that NOAC-related ICH 
have very high mortality and disability rates, similar to warfa-
rin-related ICH.3,16 It is therefore important to consider stroke 
prevention measures that do not rely on long-term anticoagu-
lation in patients who have a higher hemorrhagic risk. Such 
patients include survivors of any type of ICH, people having 
imaging markers of higher ICH risk such as microbleeds, corti-
cal superficial siderosis, moderate-to-severe white matter dis-
ease, older adults with dementia or high risk of falling, and pa-
tients with past history of bleeding in a different organ system. 
The neurologic conditions that increase ICH risk are further de-
tailed in another article from this issue and a recent review.3,8 
LAA is known to be the site of thrombus in over 90% of 
NVAF patients with an embolic event.32 The complex morpho-
logical features of the LAA are a possible explanation for this.33 
Several different methods have been developed to exclude LAA 
from left atrium, and therefore systemic circulation. These 
methods include pure endocardial closure (least invasive), hy-
brid endocardial and epicardial exclusion, and surgical oblitera-
tion (Table 2 and Figure 2). Only one endocardial approach, 
WATCHMAN device, has been studied in phase 3 RCTs against 
warfarin for clinical stroke prevention (Figure 2A). The first 
study, Watchman Left Atrial Appendage System for Embolic 
Protection in Patients with Atrial Fibrillation (PROTECT AF), 
showed both non-inferiority and superiority of this approach 
for overall stroke prevention as well as significant reductions in 
ICH and mortality when compared to the warfarin arm.34 The 
second RCT was not powered to demonstrate clinical benefit 
but its analysis failed to show noninferiority to warfarin de-
spite similar numerical event numbers, mainly due to an unex-
pectedly low stroke rate in the warfarin arm.35 LAAC using 
WATCHMAN was approved by FDA for NVAF patients who need 
anticoagulation for stroke prevention and have an appropriate 
rationale to seek a nonpharmacological alternative to warfa-
rin.3 These patients typically need OAC for 6 weeks after the 
procedure to prevent device thrombosis, followed by dual anti-
platelets for another 4.5 months after which they are main-
Table 1. Summary of non-vitamin K antagonist oral anticoagulant studies
Study Patients NOAC Comparison Outcome Conclusions for NOAC vs. warfarin
Connolly et al. (2009)24 
RE-LY trial
NVAF, mean 
CHADS2=2.1, no 
prior ICH, CrCl 
≥30 mL/min
Dabigatran 150 
mg twice daily 
(n=6,076)
Warfarin, target 
INR=2–3, mean 
TTR=64% 
(n=6,022)
Stroke, systemic embolism, 
death, major bleeds (ICH, 
GI) during 2 years of follow-
up
Noninferior for stroke/embolism & ma-
jor bleeds, lower ICH risk but higher 
for GI bleeds, MI, GI upset with dabig-
atran, permanent discontinuation 
(21.2% vs. 16.6%)
Patel et al. (2011)25 
ROCKET AF trial
NVAF, mean 
CHADS2=3.5, no 
prior ICH, CrCl 
≥30 mL/min
Rivaroxaban 20 
mg once daily 
(n=7,131)
Warfarin, target 
INR=2–3, mean 
TTR=55% 
(n=7,133)
Stroke, systemic embolism, 
death, major bleeds (ICH, 
GI) during 1.94 years of fol-
low-up
Noninferior for stroke/embolism & ma-
jor bleeds, lower ICH risk but higher 
for GI bleed with rivaroxaban, perma-
nent discontinuation (23.7% vs. 
22.2%)
Granger et al. (2011)26 
ARISTOTLE trial
NVAF, mean 
CHADS2=2.1, no 
prior ICH, CrCl 
≥25 mL/min
Apixaban 5 mg 
twice daily 
(n=9,120)
Warfarin, target 
INR=2–3, mean 
TTR=62% 
(n=9,081)
Stroke, systemic embolism, 
death, major bleeds (ICH, 
GI) during 1.8 years of fol-
low-up
Noninferior for stroke/embolism & ma-
jor bleeds, lower ICH risk with apixa-
ban, permanent discontinuation 
(25.3% vs. 27.5%)
Giugliano et al. (2013)27 
ENGAGE AF-TIMI 48 
trial
NVAF, mean 
CHADS2=2.8, no 
prior ICH, CrCl 
≥30 mL/min
Edoxaban 60 mg 
once daily 
(n=7,035)
Warfarin, target 
INR=2–3, mean 
TTR=66% 
(n=7,036)
Stroke, systemic embolism, 
death, major bleeds (ICH, 
GI) during 2.8 years of fol-
low-up
Noninferior for stroke/embolism & ma-
jor bleeds, lower ICH risk with edoxa-
ban, permanent discontinuation 
(34.4% vs. 34.5%)
NOAC, non-vitamin K antagonist oral anticoagulant; RE-LY, The Randomized Evaluation of Long-Term Anticoagulation Therapy; NVAF, nonvalvular atrial fibril-
lation; CHADS2, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke (double weight); CrCl, creatinine clearance; INR, international 
normalized ratio; TTR, time in therapeutic range; ICH, intracranial hemorrhage; GI, gastrointestinal; MI, myocardial infarction; ROCKET AF, The Rivaroxaban 
Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; ARISTOTLE, 
Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; ENGAGE AF-TIMI 48, The Effective Anticoagulation with Factor Xa 
Next Generation in Atrial Fibrillation—Thrombolysis in Myocardial Infarction 48 trial.
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Table 2. Summary of left atrial appendage closure studies
Study Patients Intervention Comparison Outcome Conclusions for LAAC
Reddy et al. (2014)34 
PROTECT AF trial
NVAF with mean 
CHADS2=2.2
LAA closure with 
the WATCHMAN® 
device, antithrom-
botic protocol 
(n=463)
Warfarin, target 
INR=2–3, mean 
TTR=66% (n=244)
Stroke, systemic embolism, 
death, major bleeds (ICH, 
GI) during 3.8 years of fol-
low-up
Noninferior for all stroke/embolism; su-
perior for mortality and ICH preven-
tion against warfarin
Holmes et al. (2014)35 
PREVAIL trial
NVAF with mean 
CHADS2=2.6
LAA closure with 
the WATCHMAN® 
device, antithrom-
botic protocol 
(n=269)
Warfarin, target 
INR=2–3, mean 
TTR=68% (n=138)
Early/late (18 months) safety 
and efficacy
Improved procedural safety, noninferior 
for prevention of ischemic stroke and 
systemic embolism >7 days post-pro-
cedure against warfarin
Tzikas et al. (2016)37  
A retrospective obser-
vational study
NVAF with mean 
CHADS2=2.8
LAA closure with 
the AMPLATZER® 
Cardiac Plug, an-
tithrombotic pro-
tocol (n=1,047)
Not available Procedural safety and feasi-
bility, 13-month follow-up 
Successful implantation (97.3%), cardi-
ac tamponade (1.24%), procedure-re-
lated stroke (0.86%), device emboliza-
tion (0.77%), procedure-related 
deaths (0.76%), annual stroke rate 
(2.3%)
Reddy et al. (2017)36  
A national clinical 
registry study in the 
U.S.
NVAF, consecu-
tive WATCH-
MAN® cases af-
ter FDA ap-
proval
LAA closure with 
the WATCHMAN® 
device, antithrom-
botic protocol 
(n=3,822)
Not available Procedural performance and 
complication rates within 7 
days
Successful implantation (95.6%), cardi-
ac tamponade (1.02%), procedure-re-
lated stroke (0.078%), device emboli-
zation (0.24%), procedure-related 
deaths (0.078%)
Post WATCHMAN (Boston Scientific) antithrombotic protocol includes warfarin for 6 weeks followed by clopidogrel for 4.5 months and indefinite aspirin use. 
Post AMPLATZER (St. Jude Medical) antithrombotic protocol includes aspirin and clopidogrel for 3 months followed by indefinite aspirin use.
LAAC, left atrial appendage closure; PROTECT AF, Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation; NVAF, 
nonvalvular atrial fibrillation; CHADS2, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke (double weight); LAA, left atrial append-
age; INR, international normalized ratio; TTR, time in therapeutic range; ICH, intracranial hemorrhage; GI, gastrointestinal; PREVAIL, Watchman LAA Closure 
Device in Patients with Atrial Fibrillation Versus Long Term Warfarin Therapy; FDA, U.S. Food and Drug Administration.
Figure 2. Left atrial appendage (LAA) closure devices and schematics of their deployment. Different types of LAA closure devices are seen. Endocardial devices in-
clude (A) WATCHMAN™ (image provided courtesy of Boston Scientific, c2018 Boston Scientific Corporation or its affiliates, http://www.bostonscientific.com) and 
(B) AMPLATZER™ AMULET™ (reproduced with permission of St. Jude Medical, c2018, https://www.sjmglobal.com). (C) The hybrid (endocardial and epicardial) LAR-
IAT™ suture delivery system for LAA exclusion (reproduced with permission of SENTREHEART, c2018, http://www.sentreheart.com) and (D) AtriClip™ for surgical 
clipping (reproduced with permission of AtriCure, c2018, https://www.atricure.com). Devices are trademarks of their respective companies, all rights reserved.
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tained on aspirin. WATCHMAN is commonly used in NVAF pa-
tients at higher hemorrhagic risk and the post-marketing expe-
rience has shown a favorable safety profile (Table 1).36 
AMPLATZER AMULET (St. Jude Medical, St. Paul, MN, USA) 
device (Figure 2B), a different type of pure endocardial LAA Oc-
cluder (St. Jude Medical) showed good safety profile in one ob-
servational study; an RCT comparing its safety and efficacy 
against WATCHMAN is currently underway.37 Another interest-
ing feature of AMPLATZER AMULET device is that the observa-
tional studies mostly used 3 months of dual antiplatelets with 
acceptable safety profile. LARIAT suture delivery system (Sen-
treHeart, Redwood City, CA, USA) provides a hybrid approach 
that involves both endocardial and epicardial access, that does 
not leave any foreign object within the heart (Figure 2C).38 As a 
result, the observational studies used only aspirin after suc-
cessful LAA exclusion with LARIAT. Currently the AMAZE trial 
aimed at comparing the safety and efficacy of LARIAT based 
LAA ligation together with pulmonary vein isolation (PVI) to 
PVI without LAA exclusion is ongoing. This study will provide 
information on LARIAT procedure use in conjunction with PVI 
compared to PVI alone. Another device, the AtriClip (AtriCure, 
Mason, OH, USA) is used during cardiac surgeries to clip the 
LAA (Figure 2D). The device has shown higher success rates 
(>95%) than surgical ligation or stapling.39 Overall, the proce-
dural risks such as pericardial effusion, device embolization, 
stroke, and death should be discussed with every patient plan-
ning to undergo LAAC. LAAC methods have become an impor-
tant aspect of stroke prevention in NVAF patients at high hem-
orrhagic risk.
The final stroke prevention approach in NVAF should always 
be determined based on a shared decision-making meeting 
with the patient and family, after a thorough discussion of 
concurrent risks and benefits of different approaches. 
Secondary stroke prevention in patients 
with patent foramen ovale
PFO is frequently detected in patients with ischemic stroke. 
While PFO is convincingly responsible for the etiology in some 
stroke patients, it may also be considered an incidental finding 
in others. PFO has regained attention in stroke practice after 
announcement of the positive percutaneous PFO closure stud-
ies in 2017 (Table 3 and Figure 3).4-6,40,41 However, incorporating 
this preventive approach into daily clinical practice is challeng-
ing. Well-known causes of ischemic stroke such as large vessel 
disease, AF and cerebral small vessel disease should be appro-
priately ruled out with detailed testing before attributing a 
stroke to PFO. Such testing might involve long-term cardiac 
monitoring with ICM in addition to routinely performed brain 
magnetic resonance imaging (MRI) and cardiovascular testing 
such as computed tomography angiography (CTA)/magnetic 
resonance angiography (MRA) and echocardiography. If one of 
these more common etiologies is confirmed, preventive mea-
sures should be selected accordingly. Once the known stroke 
etiologies are ruled out, the potential cause-and-effect rela-
tionship between PFO and stroke should be reviewed. This sec-
tion thus starts with a concise but adequately detailed review 
of the connection between PFO and stroke.
PFO is an interatrial foramen that provides a conduit for left 
atrial blood flow from the right atrium in fetal life, expected to 
close soon after initiation of breathing at birth. However, com-
plete closure does not happen in about one-fourth of the gen-
eral population.42 When PFO remains open, it is not a real hole-
like aperture, but rather a door-shaped channel. The blood pas-
sage through this door, called as right-to-left shunt (RLS), oc-
curs after increase in the right atrial pressures if not present in 
the resting state. The major mechanism of ischemic stroke in 
the setting of PFO is “paradoxical embolism,” in which the 
thromboembolic material originating from veins in the leg 
reaches the cerebral circulation after passing through the PFO 
because of RLS. Ischemic strokes may also be caused by embo-
lism due to in situ thrombus formation in the PFO channel and/
or PFO-related atrial cardiomyopathy and/or arrhythmia asso-
ciated with the latter.
Definitive prevention of recurrent paradoxical embolism is 
achieved by closure of the PFO (Figure 3). Therefore, clarifica-
tion of the role of PFO in the occurrence of otherwise idiopath-
ic cerebral embolism is of critical importance. Broadly, ischemic 
stroke related to PFO can occur as a result of either: (1) throm-
bus formation in or around the PFO or (2) more commonly 
from paradoxical embolism of thrombus formed in the venous 
system traveling through the PFO because of RLS.
The presence of high risk PFO features might be associated 
with thrombus formation in situ. These features include several 
morphological and physiological characteristics such as large 
flow of RLS, presence of long, wide or irregular PFO channel, 
massive shunting at rest, atrial septal hypermobility, atrial sep-
tal aneurysm (ASA), complex right atrial structures such as Eu-
stachian valve and Chiari’s network.43 Probably, flow grade of 
RLS is the most important one in terms of paradoxical embo-
lism, but presence of any of the other factors can suggest PFO 
as the site of thrombus formation.44
Paradoxical embolism of clot formed somewhere in the ve-
nous system would require demonstration of RLS and evidence 
of venous clot formation or at least a propensity to develop 
clot formation. The first criterion thus would be elevation of 
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right atrial and pulmonary artery pressures. This may be per-
manent, or it may only be elevated temporarily during the on-
set of stroke. Therefore, any temporary maneuver increasing 
pressures in the right heart (Valsalva maneuver) such as strain, 
heavy lifting, forced defecation, coitus, and diving should be 
questioned carefully in every case with suspicion of paradoxi-
cal embolism. Chronic and effortful coughing may also result 
in increased right atrial and pulmonary pressures. Permanent 
pulmonary hypertension causes include chronic obstructive 
pulmonary disease, obstructive sleep apnea, chronic and/or 
massive pulmonary thromboembolism (PTE), right-sided acute 
myocardial infarction (AMI), adult respiratory distress syn-
drome, and the trumpet player syndrome, which is an occupa-
tional condition due to chronic and zealous playing of breath-
taking instruments such as the trumpet.45 The presence of 
these factors should be assessed whenever PFO is considered 
as the cause for an ischemic stroke. Demonstration of RLS at 
rest or with Valsalva on cardiac ultrasonography confirms the 
propensity for paradoxical embolism. 
The second set of criteria for paradoxical embolism are about 
the presence of deep vein thrombosis (DVT) and/or PTE or dem-
onstration of a hypercoagulable state. For these purposes, the 
presence of DVT in the lower extremity should be investigated 
by valid methods such as compression ultrasonography, com-
puted tomography, MRI, contrast venography, or scintigraphy 
in all cases with cryptogenic stroke and PFO. The presence of 
thrombus in pelvic, iliac, and caval veins should be assessed by 
pelvic magnetic resonance venography (MRV) or computed to-
Table 3. Summary of multicenter randomized clinical trials on patent foramen ovale closure
Study Patients Intervention Comparison Outcome Conclusions
Furlan et al. (2012)40 
CLOSURE I trial
PFO with recent (<6 
months) crypto-
genic stroke or TIA 
(18–60 years old)
PFO closure with the 
STARFlex Septal Closure 
System®, clopidogrel for 
6 months & aspirin in-
definitely (n=447)
Warfarin or as-
pirin or both 
(n=462)
A composite of stroke/
TIA, death
Lower rate of composite end point in clo-
sure group (5.5% vs. 6.8%) but statisti-
cally not significant (2-year mean follow-
up)
Meier et al. (2013)41 
PC trial
PFO with cryptogenic 
stroke, TIA, or a pe-
ripheral thrombo-
embolic event (<60 
years old)
PFO closure with AM-
PLATZER PFO Occluder®, 
ticlopidine/clopidogrel 
for 1–6 months & aspi-
rin for ≥5 months 
(n=204)
Antiplatelet 
therapy or oral 
anticoagula-
tion (n=210)
A composite of death, 
nonfatal stroke, TIA, 
or peripheral embo-
lism
Lower rate of composite end point in clo-
sure group (3.4% vs. 5.2%) but statisti-
cally not significant (4-year mean follow-
up)
Mas et al. (2017)4 
CLOSE trial
PFO with recent (<6 
months) stroke at-
tributed to PFO, and 
atrial septal aneu-
rysm or large inter-
atrial shunt (16–60 
years old)
PFO closure, DAPT for 3 
months followed by 
antiplatelet therapy in-
definitely (n=238)
Antiplatelet 
therapy only 
arm (n=235) & 
oral anticoag-
ulation arm 
(n=187)
Occurrence of fatal or 
nonfatal stroke
Significantly lower stroke risk in closure 
group compared to antiplatelet arm (0% 
vs. 6%) but an increased risk of atrial fi-
brillation after closure (4.6% vs. 0.9%).
Stroke rate 1.5% in anticoagulation group 
vs. 3.8% in the matched antiplatelet-only 
subcohort (5-year mean follow-up)
Saver et al. (2017)5 
RESPECT trial
PFO with cryptogenic 
ischemic stroke 
(<270 days) (18–60 
years old)
PFO closure with the 
AMPLATZER PFO Oc-
cluder®, DAPT for 1 
month followed by as-
pirin only for 5 months, 
then antithrombotic 
use per treating physi-
cian (n=499)
Any antiplatelet 
therapy or oral 
anticoagula-
tion (n=481) 
A composite of recur-
rent nonfatal or fatal 
ischemic stroke, or 
early death after ran-
domization
Significantly lower rate of recurrent isch-
emic strokes (3.6% vs. 5.8%) but higher 
venous thromboembolism in the closure 
arm (3.4% vs. 0.8%) (5.9-year median 
follow-up)
Søndergaard et al. 
(2017)6 Gore RE-
DUCE Clinical 
Study
PFO with cryptogenic 
stroke (<180 days), 
81% with moder-
ate/large interatrial 
shunts (18–59 
years old)
PFO closure with the He-
lex Septal Occluder® or 
the Cardioform Septal 
Occluder®, 300 mg 
clopidogrel load then 
antiplatelet monother-
apy (n=441)
Any antiplatelet 
monotherapy 
(n=223)
Co-primary end points: 
(1) Clinical ischemic 
stroke, (2) composite 
of clinical ischemic 
stroke or silent brain 
infarction detected on 
imaging
Significantly lower clinical ischemic stroke 
(1.4% vs. 5.4%) but higher rates of device 
complications (1.4%) and atrial fibrilla-
tion (6.6% vs. 0.4%) in the closure arm 
(3.2-year median follow-up)
CLOSURE I, Evaluation of the STARFlex Septal Closure System (NMT Medical Inc.) in Patients with a Stroke and/or Transient Ischemic Attack due to Presumed 
Paradoxical Embolism through a Patent Foramen Ovale; PFO, patent foramen ovale; TIA, transient ischemic attack; PC trial, Clinical Trial Comparing Percutaneous 
Closure of Patent Foramen Ovale Using the AMPLATZER (St. Jude Medical) PFO Occluder (St. Jude Medical) with Medical Treatment in Patients with Cryptogenic 
Embolism; CLOSE, Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence; DAPT, dual antiplatelet therapy 
(aspirin and clopidogrel); RESPECT, Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment; Gore 
REDUCE Clinical Study, GORE® HELEX® Septal Occluder and GORE® CARDIOFORM Septal Occluder for Patent Foramen Ovale (PFO) Closure in Stroke Patients.
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mographic venography.46 Pelvic MRV can also show the pres-
ence of May-Thurner anatomy characterized by compression of 
the left common iliac vein by the overlying right common iliac 
artery, a condition that can result in compression of the com-
mon venous outflow tract of the left lower extremity increas-
ing the risk of DVT. Plasma D-dimer level elevation can be used 
as a screening tool for DVT diagnosis.47 If DVT cannot be docu-
mented, this criterion may be met by the presence of DVT risk 
factors, especially useful in non-acute situations. In other 
words, the inability to demonstrate DVT does not rule out the 
possibility of paradoxical embolism. In this context, immobility, 
occult hereditary thrombophilia, oral contraceptive use, preg-
nancy and postpartum period, and May-Thurner anatomy in-
crease the risk. 
For every patient, activated protein C resistance, factor-5 
Leiden mutation, antiphospholipid antibody titers, prothrombin 
20210 polymorphism, homocysteine levels, and associated 
methylenetetrahydrofolate reductase mutations, should be 
tested for thrombophilia detection. Protein S, protein C, anti-
thrombin III and factor VIII concentrations and/or activities 
should be studied in patients without these factors.48 Long 
plane travel (“economy-class stroke syndrome”) is a risk for 
embolism in patients with PFO.49 In addition, several surgical 
procedures such as neurosurgical posterior fossa surgery, intra-
medullary orthopedic surgery, lower limb venous surgery, lipo-
suction and any laparoscopy carry high stroke risk if RLS is 
present. Another important point regarding DVT testing is that 
DVT may develop very rapidly after stroke onset, and it is abso-
lutely necessary to carry out the examination within the first 
few days after stroke (or immobility) onset. If the DVT is de-
tected later, it cannot be established whether the DVT is either 
the cause or the result of the stroke. Even if the initial stroke is 
not due to PFO, the development of DVT confers a high-risk 
status for stroke recurrence in paretic stroke patients with PFO. 
Ttranscatheter PFO closure may sometimes be considered in 
such situations as well.
Current options to prevent ischemic stroke recurrence attrib-
uted to PFO include antiplatelet medications, anticoagulants, 
and transcatheter PFO closure. The choice between antiplatelet 
and anticoagulant agents for secondary prophylaxis is based on 
the status of the systemic and hematological factors. It should 
be noted that there is no significant difference for ischemic pre-
vention between the two groups of drugs in the absence of 
thrombophilia or DVT/PTE.50 Long-term use of OACs would in-
crease the risk of hemorrhagic complications and most impor-
tantly fatal/disabling ICH.3 On the other hand, if a hypercoagula-
ble state that requires life-long anticoagulation such as anticar-
diolipin antibody syndrome is found, long-term anticoagulation 
is the only option although PFO closure might still have a role in 
these situations. It is important to remember that medical man-
Figure 3. Schematic of patent foramen ovale (PFO) closure. Schematic illustrating the endovascular procedure used to close a PFO using AMPLATZER™ PFO 
Occluder (St. Jude Medical). (A) The catheter is inserted through the PFO, (B, C) followed by expansion of the left sided disc and (D) deployment of the device 
to occlude the PFO (showing the device in place). AMPLATZER and St. Jude Medical are trademarks of St. Jude Medical, LLC or its related companies. Repro-
duced with permission of St. Jude Medical, c2018 (https://www.sjmglobal.com). All rights reserved.
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agement should involve aggressive detection and control of all 
vascular risk factors in patients with PFO and stroke.
Five recently-published RCTs showed that transcatheter PFO 
closure plus antiplatelet treatment is superior to antiplatelet 
therapy alone for secondary stroke prevention (Table 3 and Fig-
ure 3).4-6,40,41 These studies showed that the frequency of recur-
rent embolic stroke can be reduced from 1.1 to 0.53 per 100 
patient-years with the transcatheter PFO closure, corresponding 
to 50% relative risk reduction, 2.11% absolute risk reduction, 
and a number needed to treat of 46.5 over about 4 years follow-
up.51-53 There was no significant difference in the risk of tran-
sient ischemic attack, mortality and bleeding rates between 
transcatheter PFO closure and antiplatelet-only approaches. The 
most noticeable adverse effect during post-transcatheter PFO 
closure period is an increase in the frequency of AF (1.3 vs. 0.25 
in 100-patient years, referring to an approximately five times 
relative risk increase).51 Many of the AF episodes are transient 
and limited to the periprocedural phase. Indeed, three quarters 
of these post-transcatheter PFO closure AF episodes occur 
within 45 days, and almost all disappear in up to 6 months. It is 
recommended for these patients to receive anticoagulants for 6 
months, provided that persistent normalization of the rhythm 
can be confirmed. The studies assessing PFO closure used only a 
simple EKG or short-term Holter to rule out concomitant AF; so, 
the extent of AF in these patients is not well-known. In addi-
tion, an increase in venous thromboembolism frequency was 
noted in cases of switching anticoagulants to antiplatelets after 
PFO closure in patients with thrombophilia.
Despite the high popularity in medical and lay social media, 
these recent data did not change routine clinical practice in 
PFO management. Some of the concerns voiced are that: (1) 
none of these studies was completely blinded; (2) the rates of 
lost to follow-up and withdrawal of consent were high; (3) the 
enrollment criteria were heterogenous and restrictive; and (4) 
different devices and especially different antithrombotic regi-
mens were used.54,55
In the light of the findings summarized above, we believe 
that transcatheter PFO closure is indicated in a number of clin-
ical scenarios. In case of PFO and otherwise cryptogenic embo-
lism, PFO should be closed if recurrence occurs despite medical 
treatment. These patients should continue taking antiplatelet 
medication thereafter. Anticoagulant therapy should be used 
after first embolic event in cases with thrombophilia or docu-
mented DVT/PTE. If a recurrence occurs despite well-managed 
anticoagulation, the PFO should then be closed. Standard 
thrombosis management guidelines should be applied for 
medical treatment selection. PFO closure may be reasonable in 
some instances after the first embolic episode. Cerebral MRI, 
obtained during the index stroke, documenting one or more 
previous embolic (cortical) infarcts, contraindications to use of 
long-term anticoagulants or antiplatelets and high-risk fea-
tures of PFO would support PFO closure especially in the young 
patient with high-flow RLS. Waiting for recurrence, that is, a 
second stroke with associated disability/death risks, would not 
be rational in these cases. It is appropriate to reiterate that 
there are no data suggesting that every PFO should be closed 
following the first embolic event. PFO closure for primary pro-
phylaxis is not recommended for any reason including migraine 
with aura in subjects who never experienced clinical paradoxi-
cal embolism, as there are no objective data showing the ben-
efit of closure in these situations.
In patients with stroke due to PFO, the risk of embolism re-
currence is very low after complete PFO closure. It is well 
known that shunt retention after percutaneous PFO closure is 
about 10%. However, these residual shunts do not lead to an 
increased embolism risk because their sizes are very small, and 
their apertures are meshed with the device.56 Therefore, if there 
is an ischemic stroke recurrence after percutaneous PFO clo-
sure, it is more likely to be related to a different etiologic 
mechanism. It should be remembered that PFO closure would 
only prevent ischemic strokes attributable to PFO and decrease 
the risk of bleeding related to long-term anticoagulant use. In 
conclusion, the PFO stroke relationship must be carefully as-
sessed for each patient, and treatment decisions should involve 
a multidisciplinary team as well as a formal shared decision-
making process. 
Stroke in infective endocarditis
IE is a microbial infection of the cardiac endocardial surface 
including valves (native and prosthetic) and pacemakers/im-
plantable cardioverter-defibrillator (ICD) wires. The vast major-
ity of IEs are bacterial, while only a few are fungal. Culture re-
mains negative in up to one-fifth of IE cases. The incidence of 
IE is about 3 to 10 per 100,000. A predisposing heart disease is 
found in approximately 75% of cases.57 Various IE classifica-
tions are available. For practical purposes, IE is divided into 
four groups: (1) left-sided native valve IE (NVIE); (2) left-sided 
prosthetic valve IE (PVIE), further classified as early, if devel-
oped in the first year after valve implantation, or late thereaf-
ter; (3) right-sided IE; and (4) device-related IE. Right-sided IE 
is usually associated with intravenous (IV) drug use and causes 
fewer neurovascular complications if confined to the right 
heart. The most frequent cause of acute IE, which is overall less 
common (up to 20%) compared to other type IEs is Staphylo-
coccus aureus (SA). SA-IE usually occurs in natural valves, re-
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sulting in a more rapidly progressive and destructive infection. 
The most common cause of subacute NVIE is viridans group 
streptococcus (VGS), which causes an erosive IE that frequently 
develops on previously diseased and deformed valves. The most 
common cause of PVIE is coagulase negative staphylococcus.58
Significant systemic symptoms of IE are related to fever, HF, 
valve insufficiency, cerebral and peripheral embolism. Neuro-
logical involvement associated with IE is common, and diverse. 
Approximately half of IE patients have neurological complaints 
at admission including focal deficits, encephalopathy, and epi-
leptic seizures. Cerebral abscesses and meningitis are not un-
common. Symptomatic neurovascular events include septic 
(infectious) cerebral embolism, central nervous system (CNS) 
hemorrhages, and mycotic aneurysms. Neurological complica-
tions are more prevalent in the early course, usually before ini-
tiation of the first dose of antibiotics, and their occurrence 
generally indicates poorer prognosis. In this section, we will fo-
cus on cerebral septic embolism, IE-related CNS hemorrhages, 
and intracranial mycotic aneurysms (ICMAs). With advances in 
MRI techniques, previously less well-known pathologies such 
as microbleeds, superficial siderosis and smaller infarcts are 
commonly detected nowadays in IE clinical practice necessitat-
ing neurology consultations. 
The frequency of systemic embolism in IE is 22% to 50%. 
Approximately two-thirds of these embolizations involve cere-
bral circulation. The middle cerebral artery (MCA) territory is 
affected in up to 90% of IE cases with stroke. Diffusion MRI 
studies have shown that cerebral microembolisms are present 
in almost every IE case, albeit mostly clinically occult.59 Mitral 
valve involvement is associated with a high risk of stroke, es-
pecially if anterior leaflets are infected. SA, candida, and 
HACEK (Haemophilus species, Aggregatibacter species, Cardio-
bacterium hominis, Eikenella corrodens, and Kingella species) 
group organisms are linked to higher embolism risk. Response 
of vegetation to the antibiotic treatment is critical. Growth of 
vegetation under antibiotic treatment without shrinkage after 
4 to 8 weeks of treatment are significant risk factors along 
with several morphological vegetation features such as high 
mobility, irregular shape, sessile, and loose attachment. Embo-
lism risk increases if the size of left-sided vegetation is greater 
than 1 cm, albeit it is stated that this may be a more relevant 
criterion for VGS IE.60 Stroke frequency is significantly reduced 
after 2 to 3 weeks of effective IV antibiotic therapy. Such de-
crease in risk is independent of IE location and offending mi-
croorganism type.58 Non-infectious CE may also occur in the 
setting of IE due to associated cardiac diseases.
An important current discussion topic in IE is about the value 
of cerebral MRI in the clinical decision-making processes.61 Ce-
rebral MRI may be considered in all patients with left-sided IE 
even in the absence of CNS signs and symptoms. In a seminal 
French study, MRI documented at least one category of lesions 
in 82% of 106 IE patients, including ischemic lesions in 68, mi-
crohemorrhages in 74, and silent aneurysms in 10, albeit only 
12% of them had acute neurologic symptoms.62 Brain MRI 
findings (microinfarcts, cerebral microbleeds [CMBs], ICMAs, 
and leptomeningeal contrast enhancement) may assist in not 
only tailoring subsequent medical and surgical management, 
but also clarification of ischemic/hemorrhagic risks. MRI fre-
quently shows multi-territorial cortical and subcortical embolic 
infarcts of various diameter in IE. The more specific forms are 
numerous, multi-territorial, punctate infarcts creating a “star-
ry-sky view on diffusion-weighted imaging (DWI)” and combi-
nation of multiple microinfarcts and microabscesses.63 Clinical-
ly, multifocal and poorly localized symptoms and signs are fre-
quent. Focal findings and encephalopathy can be seen together. 
A non-focal embolic encephalopathy is a less common, but 
more typical manifestation of IE.63
Acute ischemic stroke management in IE differs from other 
diseases in many respects. Firstly, standard IV tissue plasmino-
gen activator administration in the acute phase is not safe due 
to high bleeding rates so this approach should be avoided.64 
Experience indicates that mechanical thrombectomy can be 
performed more safely in the setting of IE.65 In addition, anti-
coagulant treatment is highly perilous before complete control 
of infection (confirmed by three negative blood cultures) and 
confirmation of the lack of mycotic aneurysms or other pathol-
ogy associated with high ICH risk. The risk of CNS hemorrhagic 
complications due to anticoagulants may not be completely 
excluded even with documentation of absence of cerebral sep-
tic vasculitis and/or mycotic microaneurysms with cerebral 
catheter angiography. While it might decrease the risk of non-
infected embolism from concomitant AF, if present, anticoagu-
lation does not prevent septic emboli and associated infarcts. 
Antiplatelets have no role. In these patients, valve surgery can 
be performed after stabilization of the infection and ruling out 
a high hemorrhagic risk cerebral pathology such as ICMA. The 
most important issues are always rapid diagnosis and initiation 
of appropriate antibiotics in addition to source control.
The frequency of hemorrhagic stroke is lower than ischemic 
events in IE but indeed outcomes of ICH are dismal. Almost ev-
ery type of CNS hemorrhage such as intraparenchymal, sub-
arachnoid (SAH), subdural hematomas and hemorrhagic infarc-
tion can be seen in IE. Mitral valve involvement, SA positivity 
and large (≥30 mm) vegetations are usually linked to CNS hem-
orrhage.66 Anticoagulation before infection control and before 
ruling out ICMA or other high-risk lesions is a well-recognized 
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risk factor for CNS hemorrhage. Importantly, the cardiac and 
neurological prognosis of IE-related hematomas is poor.
Two types of CNS hemorrhage merit further mentioning. The 
first is convexal, or cortical SAH (frequency, about 10%), which 
may be related to distal mycotic microaneurysm or septic arte-
ritis. In cases with MRI-documented convexal SAH or cortical 
siderosis, catheter angiography should be performed.67 The 
other subtle hemorrhagic pathology is CMBs which have a 
documented frequency of around 60% in IE based on consecu-
tive MRI studies. These CMBs have been linked to PVIE rather 
than prior anticoagulant use.68 IE-associated CMBs show sev-
eral different features such as more superficial localization, 
larger size and heterogeneous appearance.69 These are not usu-
ally due to mycotic aneurysms, but inflammatory distal arteritis 
from septic microembolism. The number and localization of 
CMBs do not correlate with DWI positive microinfarcts. The 
presence of CMBs is a strong predictor of impending CNS hem-
orrhage in early phases of IE. However, after successful control 
of infection, this risk disappears and no further increase in 
CMBs is anticipated. After full infection control, the risk of 
long-term anticoagulation might also be reduced to a reason-
able degree. Therefore, CMBs may not be considered as a con-
crete contraindication to anticoagulant use when indicated in 
these cases, once the infection is adequately treated.70 
The incidence of ICMA in IE is between 1% to 10%.71,72 IC-
MAs are more commonly seen in patients with sepsis, human 
immunodeficiency virus, and IV drug use and relative immuno-
compromised states such as diabetes. Not only incidence, but 
also risk of rapid growth and rupture increases in immune-sup-
pressed IE patients.71 Clinical manifestations of ICMAs are high-
ly variable, similar to other neurovascular manifestations of IE. 
Fever is seen in only 20% of cases with ICMAs, while focal 
neurological deficit and meningeal irritation signs are noted in 
40% along with headache in 60%. ICMAs present with SAH in 
40%, infarct in 30%, and lobar hemorrhage in another 30%, 
usually in combination. Of note, symptomatic infected cerebral 
emboli frequently, but not invariably, precede the ICMA forma-
tion. In cases with CNS hemorrhage in the setting of IE, the 
likelihood of ICMA is around 20%, and 1% in non-hemorrhagic 
cases. A catheter angiography should therefore be performed 
for every case with IE associated CNS hemorrhage. CTA cannot 
replace catheter angiography as the sensitivity of CTA varies 
between 45% to 85% if the diameter of the aneurysm is 3 mm 
or less, albeit it might reach 100% for aneurysms greater than 
3 mm.73 ICMAs are always linked to poor prognosis in IE. Their 
rupture corresponds to approximately 80% mortality rate, while 
mortality is about 30% in patients with unruptured ICMAs.72
The cerebral mycotic aneurysms are typically thin-walled 
and fragile. Rupture rate is variable (between 2% to 80%) with 
an average of 50%. However, according to some authorities, 
rupture risk may be lower than these estimates. No predictive 
factors for mycotic aneurysm rupture have been identified. It is 
well documented that the size of the aneurysm is not directly 
related to the risk of rupture.74 The average diameter of ICMAs 
is around 4 mm. The shapes are generally fusiform and irregu-
lar. Saccular geometry is less common. The most typical feature 
is their dynamic morphology; change in shape, growth, shrink-
age and emergence of new aneurysms during follow-up 
strongly suggests an infectious cause.75 ICMAs mostly develop 
in the distal cerebral vasculature. The main cause of these dis-
tal mycotic aneurysms is septic embolism. Rare occurrence of 
proximal mycotic aneurysms is usually associated with focal 
meningitis. MCA territory is involved in 70% of the cases. IC-
MAs are multiple in about one-fourth of patients.72,74 Strepto-
cocci species are the most frequent causative organisms, found 
in approximately 50% of patients with ICMA in whom a mi-
croorganism could be detected. SA is isolated in about 10% of 
these patients.60
The main component of ICMA management is parenteral 
antibiotics.57 With intensive antibiotic therapy, the aneurysm is 
expected to shrink and subsequently disappear. However, oblit-
eration of an ICMA should be performed when an open-heart 
surgery such as emergency valve replacement is needed. Since 
anticoagulation is not permitted and HF usually worsens dur-
ing post-craniotomy period, endovascular treatment methods 
are preferred to neurosurgical approaches.58 Unless ICMAs are 
located in eloquent areas such as motor cortex, occlusion of 
the parent artery proximal to the aneurysm is often the proce-
dure of choice.58 This approach is not always easy whenever 
such artery supplies a functionally important region. Discussing 
these difficult situations between neurology, cardiology, inter-
ventional neurology, and cardiothoracic surgery experts and 
involving the patient in clinical decision making is important. 
Heart failure and stroke
HF is currently grouped into two: HF with reduced ejection 
fraction (EF), previously called “systolic HF,” and HF with pre-
served EF, previously called “diastolic HF.” Low EF is diagnosed 
when it is less than 40%, while normal EF is higher than 50%. 
Values from 40% to 50% are described as “mid-range” EF.76
Prevalence of both types of HF is high, between 10% to 25%, 
in stroke cohorts. Functional outcomes and survival rates are 
significantly worse in stroke patients with HF. Major risk factors 
of HF are hypertension, coronary artery disease, heart valve dis-
eases, AF and diabetes, all of which are also important risk/etio-
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logical factors for stroke individually. Risk factors for stroke in HF 
patients without AF are previous stroke history, severity of HF 
symptoms, insulin-dependent diabetes mellitus, body mass in-
dex, and age. Elevation of B-type natriuretic peptide may also 
indicate an increased risk.77 In addition to frequently coexistent 
pathologies such as atherosclerotic arterial disease and AF, HF 
can cause stroke itself via intracardiac stasis related thrombo-
embolism along with low-cardiac output-related cerebral hypo-
perfusion and reduced cerebral autoregulation capacity.76
For HF patients with AF, anticoagulation is generally recom-
mended based on other embolic risk factors and the absence of 
concurrent hemorrhagic risk. If no AF, then the benefit of anti-
coagulation is not clear. In a meta-analysis of four trials, in-
cluding Warfarin versus Aspirin in Reduced Cardiac Ejection 
Fraction (WARCEF),78 warfarin reduced ischemic stroke fre-
quency from 1.36 to 0.72 events per 100 patient-years com-
pared to aspirin. Unfortunately, this potential benefit was ne-
gated by a significant increase in major bleeding rates from 
0.87 to 1.78 events per 100 patient-years. In addition, no im-
provement has been observed in survival rates with warfarin.76 
However, NOACs, with well-established lower bleeding rates, 
may be potentially useful for this indication and merit further 
research. COMMANDER HF is a currently ongoing phase III trial 
aiming to test rivaroxaban versus placebo for reducing the risk 
of death, myocardial infarction (MI), or stroke in patients with 
chronic HF and significant coronary artery disease after a re-
cent HF-related hospitalization.
Standard management of HF include diuretics such as min-
eralocorticoid receptor antagonist, thiazide and loop diuretics 
along with optimization of comorbidities such as pulmonary 
disease, anemia, and sleep disordered breathing. For HF with 
reduced EF, effective hypertension control with β blocker, an-
giotensin converting enzyme inhibitor, angiotensin II receptor 
blocker, angiotensin receptor-neprilysin inhibitor, mineralocor-
ticoid receptor antagonist, and nitrates are usually suggested. 
Cardiac revascularization with angioplasty or bypass surgery 
and valvular repair, if needed, may be useful in selected pa-
tients. ICDs can be used for prevention of sudden cardiac 
death. Cardiac resynchronization therapy with biventricular 
pacing may also improve survival in some patients. It is import-
ant to note that use of left ventricular assist device pumps 
(LVADP) causes significant coagulation activation and dimin-
ished pulsatility and therefore mandates anticoagulation as 
well as antiplatelet use.79 Newer LVADP such as the Heart-
Mate®3 (St. Jude Medical) decrease pump thrombosis, but not 
stroke rates.80 Clinicians should be aware of the neurological 
risk of high-intensity warfarin and combination antithrombotic 
use, especially for HF patients at high baseline hemorrhagic 
risk when LVADP is considered. 
Valve replacement and stroke
Life-long OAC therapy is mandatory in the setting of prosthetic 
mechanical heart valves to prevent valve thrombosis, systemic 
and cerebral embolism. The incidence of major bleeding is 
around 1.4 per 100 patient-years in patients treated with cou-
marin derivatives.81 In the setting of major risk for anticoagu-
lant-related bleeding, such as elderly with cerebral amyloid 
angiopathy, a primary valvular repair, bioprosthesis, or trans-
catheter aortic valve replacement are preferred instead of me-
chanical valve. It is also reasonable to insert MRI-compatible 
prostheses in patients with a high risk of stroke.
In observational studies, reinstitution of anticoagulation was 
associated with a lower risk of thromboembolic complications 
compared to no anticoagulation.82 In cases who need to re-
sume oral anticoagulation after a hemorrhage, the risk of re-
bleeding might be reduced with more strict INR control, effec-
tive blood pressure management, careful countermeasures 
against falls, avoidance of unnecessary addition of antiplatelet 
medicines and structured patient education including diet and 
medication interactions.83 Self-monitoring or self-management 
of oral anticoagulation therapy such as home-based testing 
can improve life quality and decrease risk of thromboembolic 
complications. Of note, all-cause mortality is reduced with 
self-management but not self-monitoring. Importantly, self-
monitoring or self-management have no effects on the occur-
rence of major hemorrhage.84 
Generally, OAC agents are restarted in 4 to 8 weeks after an 
ICH when there are no alternatives to reduce the risk of sys-
temic/cerebral thromboembolism due to thrombosis of the 
prosthetic valves. In such cases, the period before restarting 
anticoagulation should be individualized, taking into account 
both ischemic and hemorrhagic risks. For cases with high risk 
of thromboembolism due to mechanical valves, it is imperative 
to wait at least for the stabilization of the size of the ICH but 
OACs may need to be resumed as early as 7 days after the 
brain hemorrhage.
Coronary artery disease and stroke
The association between coronary artery disease and stroke is 
well-known; both in the early period after an AMI and in pa-
tients with chronic coronary artery problems. This association 
remains relevant despite improvement in vascular reperfusion 
methods and the management of cardiovascular risk factors. 
The rate of in-hospital stroke after AMI ranges from 0.7% to 
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2.2%.85 ICH after AMI has a reported incidence between 0.06% 
to 0.22%. Stroke after AMI remains associated with poor out-
comes with a 1-year mortality of 36.5%.86 Segmental wall mo-
tion abnormalities and aneurysm formation within the left 
ventricular wall and development of transient or permanent 
arrhythmias both in acute and chronic stages after an ischemic 
myocardial event can trigger an embolic stroke. The frequent 
use of fibrinolytics, anticoagulants, and multiple antiplatelet 
medications in this older patient population can certainly in-
crease the risk of ICH as well. 
All patients with coronary artery disease should receive opti-
mal treatment to correct vascular risk factors including hyper-
tension, diabetes, hyperlipidemia, smoking, and sedentary life 
style to name a few. Concurrent morbidities such as AF, other 
dysrhythmias and HF should be optimally treated. The choice 
and duration of antithrombotic treatment should be primarily 
determined based on the type of coronary intervention that the 
patient might need such as balloon angioplasty, stenting, or 
coronary artery bypass grafting.87 
Recent studies have shed light on use of simplified short-
term anticoagulation regimens in patients with AF who undergo 
percutaneous coronary interventions. The use of a lower dose 
NOAC (rivaroxaban or dabigatran) and single antiplatelet agent 
provided comparable results to the standard triple therapy that 
includes warfarin, aspirin and clopidogrel in these patients, in 
terms of safety and efficacy.88,89 Another recent study evaluated 
the effects of rivaroxaban with or without aspirin in stable car-
diovascular disease, in a design that not only excluded patients 
with past history of ICH but also symptomatic lacunar cerebral 
infarcts, to decrease anticoagulant-related ICHs. This study 
showed that in patients with stable cardiovascular disease 
(>90% of them with coronary artery disease), the combination 
of rivaroxaban 2.5 mg twice daily and aspirin prevented a com-
posite outcome of cardiovascular death, stroke, or MI more than 
aspirin alone (4.1% vs. 5.4%). However, there were more major 
bleeding events in the rivaroxaban-plus-aspirin group (3.1% vs. 
1.9%).90 This review of recent data therefore demonstrates that 
stroke and cardiovascular prevention in patients with coronary 
artery disease remains a rapidly evolving field. Understanding 
the concurrent ischemic/hemorrhagic risks and other relevant 
pathologies in the individual patient remains very important to 
provide optimal stroke prevention approaches. 
Conclusions
The last decade brought important progress in our understand-
ing of cardioembolic conditions and major advances in stroke 
prevention within this context. The familiarity of neurology and 
stroke specialists with these conditions is critical as these ex-
perts primarily evaluate stroke patients to understand the eti-
ology of stroke and stratify future ischemic and hemorrhagic 
risks. Multidisciplinary collaborations also require familiarity 
with these advances, as parties involved (neurologist, cardiolo-
gist, cardiothoracic surgeon) should be able to understand the 
available approaches and challenges in order to provide the 
best clinical management to the individual patient. 
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